New Stock News | Emerton BioTech's Hong Kong IPO prospectus has been invalidated.

Duality Biotherapeutics, Inc.'s Hong Kong IPO prospectus submitted on August 26, 2024 has expired after 6 months, on February 26, 2025, with Morgan Stanley, Jefferies, and CITIC Securities acting as joint sponsors at the time of submission. According to the prospectus, Duality Biotherapeutics is a global leader in the field of Antibody-Drug Conjugates (ADCs), dedicated to developing a new generation of innovative ADC drugs for patients with cancer and autoimmune diseases. The company has established a variety of pipelines with differentiation using its own ADC technology platform and is advancing these pipelines with the goal of revolutionizing cancer treatment and providing therapies that can significantly improve treatment outcomes for patients worldwide. Since its establishment in 2019, Duality Biotherapeutics has developed a highly innovative and differentiated pipeline consisting of 12 proprietary ADC candidate drugs, including: six clinical-stage ADCs with potential in indications with extensive unmet clinical needs, each ranked among the global leaders in terms of development progress for overall or major indications according to Frost & Sullivan; two next-generation bispecific ADCs (BsADCs) and one ADC for treating autoimmune diseases expected to enter clinical stages from 2024 to 2026; and several other preclinical ADCs.